Form 4: Halozyme Therapeutics Director Sells Shares Under 10b5-1 Trading Plan

Jeffrey William Henderson, a director at Halozyme Therapeutics, sold shares of common stock on March 3, 2025, under a pre-arranged trading plan.

Summary

• On March 3, 2025, Jeffrey William Henderson, a director of Halozyme Therapeutics, sold shares of the company's common stock.
• The sales were executed under a written trading plan adopted on September 17, 2024, in accordance with Rule 10b5-1.
• Two transactions occurred: the first involved the sale of 1,795 shares at a weighted average price of $57.934, and the second involved the sale of 3,205 shares at a weighted average price of $59.116.
• Following these transactions, Henderson directly owns 33,611 shares of Halozyme Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by a director could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the sale.

Key Dates